Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Combined Intercostal and Diaphragm Pacing for Artificial Respiration in Quadriplegic Patients
This study has been suspended.
Study NCT00004415   Information provided by FDA Office of Orphan Products Development
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes

October 18, 1999
June 23, 2005
May 1991
 
 
 
Complete list of historical versions of study NCT00004415 on ClinicalTrials.gov Archive Site
 
 
 
Study of Combined Intercostal and Diaphragm Pacing for Artificial Respiration in Quadriplegic Patients
 

OBJECTIVES: I. Determine whether combined intercostal muscle and diaphragm pacing can maintain full-time ventilatory support in patients with ventilatory dependent quadriplegia who are not candidates for phrenic nerve pacing alone.

II. Evaluate the efficacy of the Medlink device to produce synchronous intercostal and diagram activation in these patients.

PROTOCOL OUTLINE: Patients have a Medlink spinal cord electrode surgically implanted and attached to a radiofrequency receiver implanted subcutaneously over the anterior chest wall.

If substantial inspired volumes can be generated by intercostal pacing, a phrenic nerve cuff electrode and radiofrequency receiver are implanted, and patients undergo combined intercostal muscle and diaphragm pacing.

 
Interventional
Treatment
Quadriplegia
Device: Medlink spinal cord electrode
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Suspended
5
 
 

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Ventilator dependent quadriplegics who are not candidates for phrenic nerve pacing alone

Must have bilateral partial or unilateral phrenic nerve function

Must have been on ventilator support for at least 6 months and unweanable

--Patient Characteristics--

Cardiovascular: No active cardiovascular disease

Pulmonary: No active lung disease

Other: No active brain disease Stable condition

Both
18 Years to 49 Years
No
Contact information is only displayed when the study is recruiting subjects
 
 
NCT00004415
 
199/13307, CWRU-09169-M-91, CWRU-FDR000403
FDA Office of Orphan Products Development
Case Western Reserve University
Study Chair: Anthony F. DiMarco Case Western Reserve University
FDA Office of Orphan Products Development
September 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP